ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

ASND

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

1/29

07:41 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.

Low Report

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.

Report

1/28

09:32 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

1/28

09:32 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

1/27

06:00 pm

asnd

Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.

Medium Report

Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.

Report

1/27

04:23 pm

asnd

Ascendis Pharma initiated with an Overweight at Barclays

Medium Report

Ascendis Pharma initiated with an Overweight at Barclays

Report

1/27

04:23 pm

asnd

Ascendis Pharma initiated with an Overweight at Barclays

Medium Report

Ascendis Pharma initiated with an Overweight at Barclays

Report

1/20

11:01 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

1/20

11:01 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

1/20

10:47 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

1/20

10:47 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

1/20

08:11 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Medium Report

Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

1/20

08:11 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Medium Report

Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

1/9

09:09 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

1/9

09:09 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

1/9

07:18 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.

Medium Report

Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.

Report

12/11

08:23 am

asnd

Rating for ASND

Medium Report

Rating for ASND

Report

11/26

09:17 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Low Report

Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Report

11/20

06:01 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.

Low Report

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.

Report

11/20

06:01 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.

Low Report

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.

Report

11/18

09:02 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $220.00 price target on the stock.

Low Report

Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $220.00 price target on the stock.

Report

11/18

09:02 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $220.00 price target on the stock.

Low Report

Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $220.00 price target on the stock.

Report

11/18

09:00 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Wolfe Research. They set a "peer perform" rating and a $255.00 price target on the stock.

Low Report

Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Wolfe Research. They set a "peer perform" rating and a $255.00 price target on the stock.

Report

11/18

09:00 am

asnd

Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Wolfe Research. They set a "peer perform" rating and a $255.00 price target on the stock.

Low Report

Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Wolfe Research. They set a "peer perform" rating and a $255.00 price target on the stock.

Report

11/18

08:54 am

asnd

Rating for ASND

Low Report

Rating for ASND

Report

11/18

08:54 am

asnd

Rating for ASND

Low Report

Rating for ASND

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.